Abcuro raises $200m to take muscle disease drug to market

[cafead]

via US biotech Abcuro has reeled in $200 million in third-round financing that should allow it to complete its pivotal trial of lead drug ulviprubart and file it for approval for inclusion body myositis (IBM).

article source